Using MSCs to Beat Cancer: The Next Big MSC Application - RoosterBio Inc

Using MSCs to Beat Cancer: The Next Big MSC Application

<table class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;" cellpadding="0" cellspacing="0">
<tbody>
<tr>
<td style="text-align: center;"><a href="http://upload.wikimedia.org/wikipedia/commons/0/05/MSC_homing_capacity.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img src="http://upload.wikimedia.org/wikipedia/commons/0/05/MSC_homing_capacity.jpg" height="200" border="0" width="320" /></a></td>
</tr>
<tr>
<td class="tr-caption" style="text-align: center;">Genetically-modified MSCs home to tumor cells and<br />accumulate at the tumor site. Image adapted from<br /><a class="external free" href="http://dx.doi.org/10.1016/j.canlet.2011.02.012" rel="nofollow" style="background-color: #f7f7f7; background-image: none; color: #0b0080; font-family: sans-serif; font-size: 10px; line-height: 15px; text-align: left; text-decoration: none;">http://dx.doi.org/10.1016/j.canlet.2011.02.012</a>.</td>
</tr>
</tbody>
</table>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;">In the body, MSCs are known to home to sites of acute injury and inflammation and migrate to tumors in response to tumor secretion of growth factors, cytokines, and extracellular matrix (ECM) molecules. However, g<span style="mso-bidi-font-family: 'Times New Roman';"><span style="mso-bidi-font-family: 'Times New Roman';">iven their <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833273/">secretion of biomolecules</a>that augment new blood vessel formation, increase inflammation, and degrade the ECM (lending to tumor metastasis), MSCs may promote rather than impede tumor growth and migration, and confounding results from a number of <i style="mso-bidi-font-style: normal;">in vitro </i>and <i style="mso-bidi-font-style: normal;">in vivo </i>studies have been published to date.<span style="mso-spacerun: yes;">  </span>Furthermore, it has been suggested that the ability of MSCs to interact with malignant cells and cancer stem cells might <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872439/">preclude their safe therapeutic application</a>, particularly in patients with dormant or undiagnosed cancers. Despite these concerns, MSCs can serve as an effective ‘Trojan Horse’ for the targeted delivery of anticancer genes, proteins and drugs to tumor cells.<span style="mso-spacerun: yes;">  </span>Such targeted delivery can reduce the <a href="http://www.uihealthcare.org/2column.aspx?id=22807">unsavory systemic side effects</a> that often result from the use of anti-cancer agents, reducing patient morbidity and improving quality of life.<span style="mso-spacerun: yes;">   </span></span></span>
<p> </p>
</div>
<div class="MsoNormal" style="mso-layout-grid-align: none; mso-pagination: none; text-align: center; text-autospace: none;" align="center"></div>
<div class="MsoNormal" style="mso-layout-grid-align: none; mso-pagination: none; text-align: center; text-autospace: none;" align="center"><span style="font-family: 'Apple Chancery'; font-size: 16.0pt;"><span style="font-family: 'Apple Chancery'; font-size: 16.0pt;">MSCs can serve as an effective ‘Trojan Horse’ for the targeted delivery of anticancer genes, proteins and drugs to tumor cells.</span></span>
<p> </p>
</div>
<div class="MsoNormal" style="mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;"></div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"><span style="mso-bidi-font-family: 'Apple Chancery';">Recently, a </span><a href="http://www.ncbi.nlm.nih.gov/pubmed/24578184"><span style="mso-bidi-font-family: 'Apple Chancery';">review</span></a><span style="mso-bidi-font-family: 'Apple Chancery';"><span style="mso-bidi-font-family: 'Apple Chancery';">was published focusing not only on the application of MSCs for the targeted delivery of anti-cancer agents to tumors, but also on the molecular mechanisms of MSC accumulation in tumors, a poorly understood mechanism.<span style="mso-spacerun: yes;">  </span>For MSC-based anti-cancer therapies to be effective clinically, these mechanisms must be understood and successfully exploited.<span style="mso-spacerun: yes;">  </span>The authors identified several methods to genetically-modify MSCs that resulted in tumor growth inhibition, metastasis suppression, and prolonged survival upon MSC injection in various tumor-laden animal models.<span style="mso-spacerun: yes;">  </span>However, in addition to modification with anti-cancer agents, MSCs must be able to accumulate at the site of the tumor for effective cancer eradication.<span style="mso-spacerun: yes;">  </span><span style="mso-spacerun: yes;"> </span>The authors postulate that increasing the accumulation efficiency of MSCs at tumor sites can effectively target not only primary tumors but also metastatic lesions.<span style="mso-spacerun: yes;">  </span></span></span>
<p> </p>
</div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"></div>
<a name="more"></a><br />
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"><span style="mso-bidi-font-family: 'Apple Chancery';"><span style="mso-bidi-font-family: 'Apple Chancery';">Conventional thought has dictated that cytokine secretion by inflammatory cells within the tumor microenvironment promotes MSC recruitment and accumulation.<span style="mso-spacerun: yes;">  </span>The authors of this review, however, found that MSC accumulation at tumor sites could not be solely accounted for by cytokine-mediated migration.<span style="mso-spacerun: yes;">  </span>Interestingly, they found that MSC accumulation occurred at the junction between tumors and tumor stroma laden with blood vessels.<span style="mso-spacerun: yes;">  </span>Probing of this phenomenon revealed that MSC accumulation in tumors occurs through MSC-tumor endothelial cell (EC) adhesion mediated by vascular cell adhesion molecule (VCAM)-1 expression in MSCs.</span></span>
<p> </p>
</div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"></div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"><span style="mso-bidi-font-family: 'Apple Chancery';"><span style="mso-bidi-font-family: 'Apple Chancery';">They propose that the mechanism for MSC accumulation at tumor sites is as follows:</span></span>
<p> </p>
</div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"></div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"><span style="mso-bidi-font-family: 'Apple Chancery';"><span style="mso-bidi-font-family: 'Apple Chancery';">(1) Growth factors and chemokines recruit MSCs to the tumor microenvironment. (2) Inflammatory cytokines, including tumor necrosis factor (TNF)-alpha, stimulate MSCs and induce VCAM-1 expression.</span></span>
<p> </p>
</div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"><span style="mso-bidi-font-family: 'Apple Chancery';"><span style="mso-bidi-font-family: 'Apple Chancery';">(3) Activated MSCs attach to the tumor vasculature, penetrate and accumulate at tumor sites.</span></span>
<p> </p>
</div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;"></div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;"><span style="mso-bidi-font-family: 'Times New Roman';"><span style="mso-bidi-font-family: 'Times New Roman';">Thus, simple <a href="http://onlinelibrary.wiley.com/doi/10.1111/jcmm.12036/pdf" target="_blank">methods to prime MSCs prior to therapeutic administration</a>, using commercially-available molecules (such as TNF-alpha), may effectively promote MSC accumulation at tumor sites and allow for efficient delivery of anti-cancer agents by genetically-modified MSCs to tumors and metastatic lesions.<span style="mso-spacerun: yes;">  </span>Such targeted therapies could be more successful in tumor eradication, and potentially without the systemic effects often seen upon administration of anti-cancer drugs.<span style="mso-spacerun: yes;">   </span></span></span>
<p> </p>
</div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;"></div>
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-align: justify; text-autospace: none; text-justify: inter-ideograph;"><span style="mso-bidi-font-family: 'Times New Roman';"><span style="mso-bidi-font-family: 'Times New Roman';">Just last year, Mesoblast Ltd, Intrexon Corp, and ZIOPHARM Oncology, Inc <a href="http://investors.dna.com/phoenix.zhtml?c=249599&amp;p=irol-newsArticle&amp;ID=1867313&amp;highlight">announced a partnership</a> to develop a new class of cancer therapeutics.<span style="mso-spacerun: yes;">  </span>The press release mentions that the companies will combine Mesoblast's proprietary Mesenchymal Lineage Cells (MLCs) with Intrexon's RheoSwitch Therapeutic System® (RTS®) platform to deliver therapeutic transgenes to targeted tumors at specific sites in the body to treat lung cancer.<span style="mso-spacerun: yes;">  </span>If successful, this targeted therapy with modified MLCs could address a significant unmet clinical need.<span style="mso-spacerun: yes;">  </span>As mentioned by Mesoblast CEO, Silviu Itescu, a key to successful development of cell-based cancer therapeutics is the availability of <a href="http://www.roosterbio.com/">clinically relevant</a> cells that can be used for product development efforts and be commercially manufactured to industrial scale for off-the-shelf patient use.</span></span>
<p> </p>
<br /><span style="mso-bidi-font-family: 'Times New Roman';"><br /></span><span style="mso-bidi-font-family: 'Times New Roman';">These recent developments in MSC technology are opening up new lines of research in cancer, and will require <a href="http://www.roosterbio.com/products.php" target="_blank">high quality and well characterized MSCs</a> to shorten the time from discovery to clinical application.</span></div>
<!-- [if gte mso 9]><xml> <officedocumentsettings>  <allowpng></allowpng> </officedocumentsettings></xml><![endif]--> <!-- [if gte mso 9]><xml> <worddocument>  <view>Normal</view>  <zoom>0</zoom>  <trackmoves></trackmoves>  <trackformatting></trackformatting>  <punctuationkerning></punctuationkerning>  <validateagainstschemas></validateagainstschemas>  <saveifxmlinvalid>false</saveifxmlinvalid>  <ignoremixedcontent>false</ignoremixedcontent>  <alwaysshowplaceholdertext>false</alwaysshowplaceholdertext>  <donotpromoteqf></donotpromoteqf>  <lidthemeother>EN-US</lidthemeother>  <lidthemeasian>JA</lidthemeasian>  <lidthemecomplexscript>X-NONE</lidthemecomplexscript>  <compatibility>   <breakwrappedtables></breakwrappedtables>   <snaptogridincell></snaptogridincell>   <wraptextwithpunct></wraptextwithpunct>   <useasianbreakrules></useasianbreakrules>   <dontgrowautofit></dontgrowautofit>   <splitpgbreakandparamark></splitpgbreakandparamark>   <enableopentypekerning></enableopentypekerning>   <dontflipmirrorindents></dontflipmirrorindents>   <overridetablestylehps></overridetablestylehps>   <usefelayout></usefelayout>  </compatibility>  <mathpr>   <mathfont m:val="Cambria Math"></mathfont>   <brkbin m:val="before"></brkbin>   <brkbinsub m:val="--"></brkbinsub>   <smallfrac m:val="off"></smallfrac>   <dispdef></dispdef>   <lmargin m:val="0"></lmargin>   <rmargin m:val="0"></rmargin>   <defjc m:val="centerGroup"></defjc>   <wrapindent m:val="1440"></wrapindent>   <intlim m:val="subSup"></intlim>   <narylim m:val="undOvr"></narylim>  </mathpr></worddocument></xml><![endif]--><!-- [if gte mso 9]><xml> <latentstyles deflockedstate="false" defunhidewhenused="true" defsemihidden="true" defqformat="false" defpriority="99" latentstylecount="276">  <lsdexception locked="false" priority="0" semihidden="false" unhidewhenused="false" qformat="true" name="Normal"></lsdexception>  <lsdexception locked="false" priority="9" semihidden="false" unhidewhenused="false" qformat="true" name="heading 1"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 2"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 3"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 4"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 5"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 6"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 7"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 8"></lsdexception>  <lsdexception locked="false" priority="9" qformat="true" name="heading 9"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 1"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 2"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 3"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 4"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 5"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 6"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 7"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 8"></lsdexception>  <lsdexception locked="false" priority="39" name="toc 9"></lsdexception>  <lsdexception locked="false" priority="35" qformat="true" name="caption"></lsdexception>  <lsdexception locked="false" priority="10" semihidden="false" unhidewhenused="false" qformat="true" name="Title"></lsdexception>  <lsdexception locked="false" priority="1" name="Default Paragraph Font"></lsdexception>  <lsdexception locked="false" priority="11" semihidden="false" unhidewhenused="false" qformat="true" name="Subtitle"></lsdexception>  <lsdexception locked="false" priority="22" semihidden="false" unhidewhenused="false" qformat="true" name="Strong"></lsdexception>  <lsdexception locked="false" priority="20" semihidden="false" unhidewhenused="false" qformat="true" name="Emphasis"></lsdexception>  <lsdexception locked="false" priority="59" semihidden="false" unhidewhenused="false" name="Table Grid"></lsdexception>  <lsdexception locked="false" unhidewhenused="false" name="Placeholder Text"></lsdexception>  <lsdexception locked="false" priority="1" semihidden="false" unhidewhenused="false" qformat="true" name="No Spacing"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 1"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 1"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 1"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 1"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 1"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 1"></lsdexception>  <lsdexception locked="false" unhidewhenused="false" name="Revision"></lsdexception>  <lsdexception locked="false" priority="34" semihidden="false" unhidewhenused="false" qformat="true" name="List Paragraph"></lsdexception>  <lsdexception locked="false" priority="29" semihidden="false" unhidewhenused="false" qformat="true" name="Quote"></lsdexception>  <lsdexception locked="false" priority="30" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Quote"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 1"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 1"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 1"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 1"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 1"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 1"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 1"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 1"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 2"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 2"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 2"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 2"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 2"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 2"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 2"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 2"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 2"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 2"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 2"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 2"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 2"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 2"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 3"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 3"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 3"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 3"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 3"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 3"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 3"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 3"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 3"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 3"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 3"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 3"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 3"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 3"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 4"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 4"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 4"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 4"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 4"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 4"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 4"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 4"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 4"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 4"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 4"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 4"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 4"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 4"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 5"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 5"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 5"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 5"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 5"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 5"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 5"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 5"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 5"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 5"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 5"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 5"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 5"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 5"></lsdexception>  <lsdexception locked="false" priority="60" semihidden="false" unhidewhenused="false" name="Light Shading Accent 6"></lsdexception>  <lsdexception locked="false" priority="61" semihidden="false" unhidewhenused="false" name="Light List Accent 6"></lsdexception>  <lsdexception locked="false" priority="62" semihidden="false" unhidewhenused="false" name="Light Grid Accent 6"></lsdexception>  <lsdexception locked="false" priority="63" semihidden="false" unhidewhenused="false" name="Medium Shading 1 Accent 6"></lsdexception>  <lsdexception locked="false" priority="64" semihidden="false" unhidewhenused="false" name="Medium Shading 2 Accent 6"></lsdexception>  <lsdexception locked="false" priority="65" semihidden="false" unhidewhenused="false" name="Medium List 1 Accent 6"></lsdexception>  <lsdexception locked="false" priority="66" semihidden="false" unhidewhenused="false" name="Medium List 2 Accent 6"></lsdexception>  <lsdexception locked="false" priority="67" semihidden="false" unhidewhenused="false" name="Medium Grid 1 Accent 6"></lsdexception>  <lsdexception locked="false" priority="68" semihidden="false" unhidewhenused="false" name="Medium Grid 2 Accent 6"></lsdexception>  <lsdexception locked="false" priority="69" semihidden="false" unhidewhenused="false" name="Medium Grid 3 Accent 6"></lsdexception>  <lsdexception locked="false" priority="70" semihidden="false" unhidewhenused="false" name="Dark List Accent 6"></lsdexception>  <lsdexception locked="false" priority="71" semihidden="false" unhidewhenused="false" name="Colorful Shading Accent 6"></lsdexception>  <lsdexception locked="false" priority="72" semihidden="false" unhidewhenused="false" name="Colorful List Accent 6"></lsdexception>  <lsdexception locked="false" priority="73" semihidden="false" unhidewhenused="false" name="Colorful Grid Accent 6"></lsdexception>  <lsdexception locked="false" priority="19" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Emphasis"></lsdexception>  <lsdexception locked="false" priority="21" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Emphasis"></lsdexception>  <lsdexception locked="false" priority="31" semihidden="false" unhidewhenused="false" qformat="true" name="Subtle Reference"></lsdexception>  <lsdexception locked="false" priority="32" semihidden="false" unhidewhenused="false" qformat="true" name="Intense Reference"></lsdexception>  <lsdexception locked="false" priority="33" semihidden="false" unhidewhenused="false" qformat="true" name="Book Title"></lsdexception>  <lsdexception locked="false" priority="37" name="Bibliography"></lsdexception>  <lsdexception locked="false" priority="39" qformat="true" name="TOC Heading"></lsdexception> </latentstyles></xml><![endif]--> <!-- [if gte mso 10]><style> /* Style Definitions */ table.MsoNormalTable  {mso-style-name:"Table Normal";  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:"";  mso-padding-alt:0in 5.4pt 0in 5.4pt;  mso-para-margin:0in;  mso-para-margin-bottom:.0001pt;  mso-pagination:widow-orphan;  font-size:12.0pt;  font-family:Cambria;  mso-ascii-font-family:Cambria;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Cambria;  mso-hansi-theme-font:minor-latin;} </style><![endif]--> <!--StartFragment--> <!--EndFragment--><br />
<div class="MsoNormal" style="line-height: 115%; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;"></div>


Priya Baraniak
Priya Baraniak

Author



Leave a comment

Comments will be approved before showing up.